Item 8.01. Other Events.



On December 30, 2022, BeiGene, Ltd. ("BeiGene") announced that the Center for
Drug Evaluation of the China National Medical Products Administration has
accepted a supplemental biologics license application for tislelizumab in
patients with first-line unresectable or metastatic hepatocellular carcinoma.
The full text of this press release is filed as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.

   Exhibit No.

       99.1              Press release titled "BeiGene Announces Acceptance of 12th Regulatory
                         Submission in China for PD-1 Inhibitor

Tislelizumab" issued by BeiGene, Ltd.


                         on December 30, 2022
       104               The cover page from this Current Report on Form

8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses